Biotechnology

Company Overview of COR Therapeutics, Inc.

Company Overview

As of February 12, 2002, COR Therapeutics, Inc. was acquired by Millennium Pharmaceuticals Inc. COR Therapeutics, Inc. engages in the discovery, development, and marketing of novel therapeutic products for treating and preventing acute and chronic cardiovascular diseases. It markets INTEGRILIN (eptifibatide) Injection, its approved drug, to treat patients with acute cardiovascular disease. COR has various product development programs underway, each designed to address unmet clinical needs in the management of patients suffering from disorders, such as unstable angina, coronary angioplasty, acute myocardial infarction, stroke, and deep vein thrombosis. The company is based in South San Franci...

As of February 12, 2002, COR Therapeutics, Inc. was acquired by Millennium Pharmaceuticals Inc. COR Therapeutics, Inc. engages in the discovery, development, and marketing of novel therapeutic products for treating and preventing acute and chronic cardiovascular diseases. It markets INTEGRILIN (eptifibatide) Injection, its approved drug, to treat patients with acute cardiovascular disease. COR has various product development programs underway, each designed to address unmet clinical needs in the management of patients suffering from disorders, such as unstable angina, coronary angioplasty, acute myocardial infarction, stroke, and deep vein thrombosis. The company is based in South San Francisco, California.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.